Mast Therapeutics, Inc. (NYSEMKT:MSTX) went higher by +3.2120% to close at $ 0.0964. The company exchanged total volume of 7.44 million shares throughout course of last trade however it holds an average trading capacity of 10.88 million shares. Shares of company began trading at $0.0942 climbed to high of $0.1000 touched the low of $0.0900.
The company is trading above its 50-day moving averages of 0.0834 and down from 200-day moving averages of 0.3084. The firm has price to book ratio of 1.6386 and its price to sale ratio was 494.4596.
According to ZACKS data, different Brokerage Firms rated MSTX stock about their BUY, SELL or HOLD recommendations. 1 Week Ago, shares have been suggested as BUY from 0 brokerage firms and recommended as Strong Buy by 0 brokerage firms.0 brokerage firms have issued Sell rating for the company and Strong Sell rating was issued by 0 brokerage firms.2 brokerage firms have rated the company as a Hold. The Corporation has average brokerage recommendation (ABR) of 3 based on consensus of the brokerage firms issuing ratings.
The average true range of Mast Therapeutics, Inc.’s (MSTX) is recorded at 0.01 and the relative strength index of the stock stands 61.16. The stock price is going above to its 52 week low with 37.71% and lagging behind from its 52 week high with -86.42%. Analyst recommendation for this stock stands at 2.20. A look on the firm performance, its monthly performance is 20.50% and a quarterly performance of -76.49%. The stock price is trading downbeat from its 200 days moving average with -68.22% and down from 50 days moving average with -20.39%.
Enzon Pharmaceuticals, Inc. (PNK:ENZN) dropped -4.706% and closed the trade at $ 0.405. The company recorded a trading capacity of 0 shares below its three months average daily volume of 92.45 thousand shares. The stock’s 50-day moving average is noted at $0.378 and its 200-day moving average is stands at $0.390.
Additionally, the company has a PE ratio of 1.125 and has EPS of 0.360. The company has market capitalization of $17.91M.
ENZN stock has received ratings from many brokerage firms according to ZACKS. 1 Week Ago, shares have been rated as Buy from NA brokerage firms and NA brokerage firms say as Strong Buy. NA brokerage firms have suggested Sell for the company. NA brokerage firms have recommended as a Hold. Strong Sell rating was given by NA brokerage firms. The Company has average brokerage recommendation (ABR) of NA based on consensus of the ZACKS brokerage firms.
Enzon Pharmaceuticals Inc.’s (ENZN) has price to sale ratio of 1.43.. The stock price is moving up from its 20 days moving average with 5.00% and isolated positively from 50 days moving average with 7.56%.